New Good Cholesterol
Raising Drug Will Be Sold Stand Alone - Previously Company Planned
Combining With Lipitor For Heart Patients
July 26th 2006
|
 |
|
Lipitor |
|
The worlds largest pharmaceutical company, US based Pfizer Inc, says
they will start selling their new heart treatment drug, torcetrapib, in
a stand-alone pill. Previously the company planned to sell Torcetrapib
only in combination with Lipitor.
The New York Times reported that torcetrapib, is still being tested in
clinical trials and is at least 18 months from federal approval. So far
the clinical trials have shown that the drug raises the so-called good
cholesterol, a promising new approach to preventing heart attacks and
strokes.
Analysts on Wall Street say that torcetrapib could be the new
blockbuster medicine with sales of several billion per year. If Pfizer
had offered the drug only in combination with Lipitor, they would have
forced patients that use Zocor and other statins to switch to Lipitor to
get the benefits of torcetrapib.
The company has said it would have been cost prohibitive to test the
drug with every available statin on the market, so they originally
planned to offer it combination with Lipitor.
There is strong opposition to this from physicians. They claimed the
company was putting profits ahead of the patient’s health. According to
the physicians, it is not always easy to switch statin drugs. The new
decision by Pfizer is good news for doctors.
Dan Wilson
Best Syndication
Books on Heart Disease
Keywords and misspellings:
colesterol cholesteral stantin
stantoncoranary
micro-vascular disfunction
iscemic iskemic
ishcemic ishcemia angiograf blood presure
stroke embolism imbolism embilism embelism bloode clot |
RSS Feed to our Heart/Lung News
